Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

References

• Davies H Bignell GR Cox C Mutations of the BRAF gene in human cancer Nature 2002 417 949 954 12068308
   PubMed Web of Science ®Google Scholar
• Wan PT Garnett MJ Roe SM Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 2004 116 855 867 15035987
   PubMed Web of Science ®Google Scholar
• Jakob JA Bassett RLJr Ng CS NRAS mutation status is an independent prognostic factor in metastatic melanoma Cancer 2012 118 4014 4023 22180178
   PubMed Web of Science ®Google Scholar
• Bucheit AD Syklawer E Jakob JA Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma Cancer 2013 119 3821 3829 23922205
   PubMed Web of Science ®Google Scholar
• Flaherty KT Puzanov I Kim KB Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 2010 363 809 819 20818844
   PubMed Web of Science ®Google Scholar
• Sosman JA Kim KB Schuchter L Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 2012 366 707 714 22356324
   PubMed Web of Science ®Google Scholar
• Chapman PB Hauschild A Robert C Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 2011 364 2507 2516 21639808
   PubMed Web of Science ®Google Scholar
• Dummer R Goldinger SM Turtschi CP Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study Eur J Cancer 2014 50 611 621 24295639
   PubMed Web of Science ®Google Scholar
• Sumimoto H Imabayashi F Iwata T Kawakami Y The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J Exp Med 2006 203 1651 1656 16801397
   PubMed Web of Science ®Google Scholar
• Curtin JA Fridlyand J Kageshita T Distinct sets of genetic alterations in melanoma N Engl J Med 2005 353 2135 2147 16291983
   PubMed Web of Science ®Google Scholar
• Raman M Chen W Cobb MH Differential regulation and properties of MAPKs Oncogene 2007 26 3100 3112 17496909
   PubMed Web of Science ®Google Scholar
• Garnett MJ Marais R Guilty as charged: B-RAF is a human oncogene Cancer Cell 2004 6 313 319 15488754
   PubMed Web of Science ®Google Scholar
• Omholt K Platz A Kanter L Ringborg U Hansson J NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression Clin Cancer Res 2003 9 6483 6488 14695152
   PubMed Web of Science ®Google Scholar
• Viros A Fridlyand J Bauer J Improving melanoma classification by integrating genetic and morphologic features PLoS Med 2008 5 e120 18532874
   PubMed Web of Science ®Google Scholar
• Platz A Egyhazi S Ringborg U Hansson J Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site Mol Oncol 2008 1 395 405 19383313
   PubMed Web of Science ®Google Scholar
• Greaves WO Verma S Patel KP Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma J Mol Diagn 2013 15 220 226 23273605
   PubMed Web of Science ®Google Scholar
• Zebary A Omholt K Vassilaki I KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma J Dermatol Sci 2013 72 284 289 23993026
   PubMed Web of Science ®Google Scholar
• Rimoldi D Salvi S Liénard D Lack of BRAF mutations in uveal melanoma Cancer Res 2003 63 5712 5715 14522889
   PubMed Web of Science ®Google Scholar
• Eisen T Ahmad T Flaherty KT Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Br J Cancer 2006 95 581 586 16880785
   PubMed Web of Science ®Google Scholar
• Hauschild A Agarwala SS Trefzer U Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 2009 27 2823 2830 19349552
   PubMed Web of Science ®Google Scholar
• Tsai J Lee JT Wang W Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc Natl Acad Sci U S A 2008 105 3041 3046 18287029
   PubMed Web of Science ®Google Scholar
• Bollag G Hirth P Tsai J Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 2010 467 596 599 20823850
   PubMed Web of Science ®Google Scholar
• Poulikakos PI Zhang C Bollag G Shokat KM Rosen N RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 2010 464 427 430 20179705
   PubMed Web of Science ®Google Scholar
• Oken MM Creech RH Tormey DC Toxicity and Response Criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 1982 5 649 655 7165009
   PubMed Web of Science ®Google Scholar
• Chapman PB Hauschild A Robert C Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma Journal of Clinical Oncology 2012 30 8502
   Web of Science ®Google Scholar
• McArthur GA Chapman PB Robert C Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 2014 15 323 332 24508103
   PubMed Web of Science ®Google Scholar
• Ribas A Zhang W Chang I The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics J Clin Pharmacol 2014 54 368 374 24374975
   PubMed Web of Science ®Google Scholar
• National Cancer Institute National Cancer Institute Common Terminology Criteria for Adverse Events, NCI-CTCAE 4 2010 Available: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Accessed February 5th, 2014
   Google Scholar
• Anforth RM Blumetti TC Kefford RF Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma Br J Dermatol 2012 167 1153 1160 22804352
   PubMed Web of Science ®Google Scholar
• Robert C Sibaud V Mateus C Cherpelis BS Advances in the management of cutaneous toxicities of targeted therapies Semin Oncol 2012 39 227 240 22484194
   PubMed Web of Science ®Google Scholar
• Flaherty KT Robert C Hersey P Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 2012 367 107 114 22663011
   PubMed Web of Science ®Google Scholar
• Johnson DB Wallender EK Cohen DN Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy Cancer Immunol Res 2013 1 373 24490176
   PubMed Web of Science ®Google Scholar
• Yancovitz M Litterman A Yoon J Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma PLoS One 2012 7 e29336 22235286
   PubMed Web of Science ®Google Scholar
• Girotti MR Pedersen M Sanchez-Laorden B Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma Cancer Discov 2013 3 158 167 23242808
   PubMed Web of Science ®Google Scholar
• Smalley KS Lioni M Dalla Palma M Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas Mol Cancer Ther 2008 7 2876 2883 18790768
   PubMed Web of Science ®Google Scholar
• Straussman R Morikawa T Shee K Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 2012 487 500 504 22763439
   PubMed Web of Science ®Google Scholar
• Prahallad A Sun C Huang S Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 2012 483 100 103 22281684
   PubMed Web of Science ®Google Scholar
• Corcoran RB Ebi H Turke AB EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib Cancer Discov 2012 2 227 235 22448344
   PubMed Web of Science ®Google Scholar
• Nazarian R Shi H Wang Q Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 2010 468 973 977 21107323
   PubMed Web of Science ®Google Scholar
• Villanueva J Vultur A Lee JT Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 2010 18 683 695 21156289
   PubMed Web of Science ®Google Scholar
• Romano E Pradervand S Paillusson A Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression Clin Cancer Res 2013 19 5749 5757 23948972
   PubMed Web of Science ®Google Scholar
• Emery CM Vijayendran KG Zipser MC MEK1 mutations confer resistance to MEK and B-RAF inhibition Proc Natl Acad Sci U S A 2009 106 20411 20416 19915144
   PubMed Web of Science ®Google Scholar
• Wagle N Emery C Berger MF Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 2011 29 3085 3096 21383288
   PubMed Web of Science ®Google Scholar
• Shi H Hugo W Kong X Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer Discov 2014 4 80 93 24265155
   PubMed Web of Science ®Google Scholar
• Van Allen EM Wagle N Sucker A The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discov 2014 4 94 109 24265153
   PubMed Web of Science ®Google Scholar
• Johannessen CM Boehm JS Kim SY COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 2010 468 968 972 21107320
   PubMed Web of Science ®Google Scholar
• Montagut C Sharma SV Shioda T Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 2008 68 4853 4861 18559533
   PubMed Web of Science ®Google Scholar
• Heidorn SJ Milagre C Whittaker S Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 2010 140 209 221 20141835
   PubMed Web of Science ®Google Scholar
• Paraiso KH Haarberg HE Wood E The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms Clin Cancer Res 2012 18 2502 2514 22351686
   PubMed Web of Science ®Google Scholar
• Whittaker SR Theurillat JP Van Allen E A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition Cancer Discov 2013 3 350 362 23288408
   PubMed Web of Science ®Google Scholar
• Paraiso KH Xiang Y Rebecca VW PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression Cancer Res 2011 71 2750 2760 21317224
   PubMed Web of Science ®Google Scholar
• Nathanson KL Martin AM Wubbenhorst B Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436) Clin Cancer Res 2013 19 4868 4878 23833299
   PubMed Web of Science ®Google Scholar
• Falchook GS Trent JC Heinrich MC BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance Oncotarget 2013 4 310 315 23470635
   PubMed Web of Science ®Google Scholar
• Corcoran RB Rothenberg SM Hata AN TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma Sci Transl Med 2013 5 196ra98
   PubMed Web of Science ®Google Scholar
• Das Thakur M Salangsang F Landman AS Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 2013 494 251 255 23302800
   PubMed Web of Science ®Google Scholar
• Flaherty KT Infante JR Daud A Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 2012 367 1694 1703 23020132
   PubMed Web of Science ®Google Scholar
• Faber AC Coffee EM Costa C mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 Cancer Discov 2014 4 42 52 24163374
   PubMed Web of Science ®Google Scholar
• Sharma A Trivedi NR Zimmerman MA Tuveson DA Smith CD Robertson GP Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors Cancer Res 2005 65 2412 2421 15781657
   PubMed Web of Science ®Google Scholar
• Graells J Vinyals A Figueras A Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling J Invest Dermatol 2004 123 1151 1161 15610528
   PubMed Web of Science ®Google Scholar
• Basile KJ Le K Hartsough EJ Aplin AE Inhibition of mutant BRAF splice variant signaling by next generation, selective RAF inhibitors Pigment Cell Melanoma Res Epub 1 15 2014
   Web of Science ®Google Scholar
• Finn L Markovic SN Joseph RW Therapy for metastatic melanoma: the past, present, and future BMC Med 2012 10 23 22385436
   PubMed Web of Science ®Google Scholar
• Boni A Cogdill AP Dang P Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res 2010 70 5213 5219 20551059
   PubMed Web of Science ®Google Scholar
• Wilmott JS Long GV Howle JR Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma Clin Cancer Res 2012 18 1386 1394 22156613
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B Chodon T Sazegar H The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations Clin Cancer Res 2010 16 6040 6048 21169256
   PubMed Web of Science ®Google Scholar
• Liu C Peng W Xu C BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice Clin Cancer Res 2013 19 393 403 23204132
   PubMed Web of Science ®Google Scholar
• Callahan MK Masters G Pratilas CA Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor Cancer Immunol Res 2014 2 1
   PubMed Web of Science ®Google Scholar
• Melero I Hervas-Stubbs S Glennie M Pardoll DM Chen L Immunostimulatory monoclonal antibodies for cancer therapy Nat Rev Cancer 2007 7 95 106 17251916
   PubMed Web of Science ®Google Scholar
• Leach DR Krummel MF Allison JP Enhancement of antitumor immunity by CTLA-4 blockade Science 1996 271 1734 1736 8596936
   PubMed Web of Science ®Google Scholar
• Robert C Thomas L Bondarenko I Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 2011 364 2517 2526 21639810
   PubMed Web of Science ®Google Scholar
• Ribas A Hodi FS Callahan M Konto C Wolchok J Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 2013 368 1365 1366 23550685
   PubMed Web of Science ®Google Scholar
• Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 264 22437870
   PubMed Web of Science ®Google Scholar
• Okazaki T Chikuma S Iwai Y Fagarasan S Honjo T A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 2013 14 1212 1218 24240160
   PubMed Web of Science ®Google Scholar
• Brahmer JR Drake CG Wollner I Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 2010 28 3167 3175 20516446
   PubMed Web of Science ®Google Scholar
• Brahmer JR Tykodi SS Chow LQ Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 2012 366 2455 2465 22658128
   PubMed Web of Science ®Google Scholar
• Hamid O Robert C Daud A Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 2013 369 134 144 23724846
   PubMed Web of Science ®Google Scholar
• Topalian SL Hodi FS Brahmer JR Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 2443 2454 22658127
   PubMed Web of Science ®Google Scholar
• Taube JM Anders RA Young GD Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 2012 4 127ra37
   PubMed Web of Science ®Google Scholar
• Joseph RW Sullivan RJ Harrell R Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma J Immunother 2012 35 66 72 22130161
   PubMed Web of Science ®Google Scholar
• Khalili JS Liu S Rodríguez-Cruz TG Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma Clin Cancer Res 2012 18 5329 5340 22850568
   PubMed Web of Science ®Google Scholar
• Koya RC Mok S Otte N BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy Cancer Res 2012 72 3928 3937 22693252
   PubMed Web of Science ®Google Scholar
• Rosenberg SA Yannelli JR Yang JC Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 J Natl Cancer Inst 1994 86 1159 1166 8028037
   PubMed Web of Science ®Google Scholar
• Rosenberg SA Dudley ME Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Proc Natl Acad Sci U S A 2004 101 Suppl 2 14639 14645 15381769
   PubMed Web of Science ®Google Scholar
• Dudley ME Wunderlich JR Yang JC Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 2005 23 2346 2357 15800326
   PubMed Web of Science ®Google Scholar
• Rosenberg SA Yang JC Sherry RM Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin Cancer Res 2011 17 4550 4557 21498393
   PubMed Web of Science ®Google Scholar
• Tiacci E Trifonov V Schiavoni G BRAF mutations in hairy-cell leukemia N Engl J Med 2011 364 2305 2315 21663470
   PubMed Web of Science ®Google Scholar
• Samuel J Macip S Dyer MJ Efficacy of vemurafenib in hairy-cell leukemia N Engl J Med 2014 370 286 288 24428489
   PubMed Web of Science ®Google Scholar
• Munoz J Schlette E Kurzrock R Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation J Clin Oncol 2013 31 e351 e352 23733763
   PubMed Web of Science ®Google Scholar
• Peters S Michielin O Zimmermann S Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma J Clin Oncol 2013 31 e341 e344 23733758
   PubMed Web of Science ®Google Scholar
• Gautschi O Pauli C Strobel K A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib J Thorac Oncol 2012 7 e23 e24 22743296
   PubMed Web of Science ®Google Scholar
• Kim KB Cabanillas ME Lazar AJ Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation Thyroid 2013 23 1277 1283 23489023
   PubMed Web of Science ®Google Scholar
• Cohen Y Xing M Mambo E BRAF mutation in papillary thyroid carcinoma J Natl Cancer Inst 2003 95 625 627 12697856
   PubMed Web of Science ®Google Scholar
• Kopetz SJD Chan E Hecht JR PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors J Clin Oncol 2010 28 15 (suppl;abstr 3534)
   Google Scholar
• Rajagopalan H Bardelli A Lengauer C Kinzler KW Vogelstein B Velculescu VE Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 2002 418 934 12198537
   PubMed Web of Science ®Google Scholar